Henry Ford Hospital Medical Journal
Volume 37

Number 2

Article 9

6-1989

Myasthenia Gravis
Stanton B. Elias

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Elias, Stanton B. (1989) "Myasthenia Gravis," Henry Ford Hospital Medical Journal : Vol. 37 : No. 2 , 81-85.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol37/iss2/9

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.
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Myasthenia Gravis*
Stanton B. Elias, MD^

D

uring the past two decades the concept of myasthenia gravis
has changed radically. At one time myasthenia gravis was
defined as a neuromuscular disease affecting voluntary skeletal
muscles and producing weakness and fatigability. Myasthenia
gravis was subsequently classified as an autoimmune disease in
which antibodies directed against the acetylcholine receptor
produce neuromuscular failure, weakness, and fatigability.
Much of the pathophysiology of this disease has evolved in the
last 20 years, and myasthenia gravis can now be considered as a
prototype in terms of understanding the pathogenesis of many
other autoimmune diseases.

Pathophysiology
In the 1960s there was great controversy about whether myasthenia gravis was a presynaptic disease, something that
evolved from an abnormality in the packaging or manufacture of
acetylcholine in the presynaptic terminal in the neuromuscular
junction, or a postsynaptic disease, an abnormality in the acetylcholine receptor or in the transduction of the signal in the muscle
membrane to produce muscle contraction. In the mid 1960s,
Elmqvist and Lambert (1) found that the miniature end plate potential—the small depolarization of the postsynaptic membrane
that came from the spontaneous release of a single quantum of
acetylcholine—was reduced in amplitude to about 10% to 30%
of normal. From another set of experiments, which was limited
by the technology at that time, they thought that the postsynaptic
membrane had a normal sensitivity and therefore suggested that
myasthenia gravis was a presynaptic abnormality that resulted
from small packets of acetylcholine being released (1). This was
the predominant belief throughout the 1960s. However, in 1971,
Engel and Santa's (2) morphometric electron microscopic studies of the postsynaptic membrane produced the following
results:
1. The projections of the postsynaptic membrane where the
acetylcholine receptors reside, the postsynaptic villi, were
markedly altered and, in fact, destroyed.
2. The presynaptic structures, the nerve terminals, were normal. The size of the presynaptic vesicles was normal, and the
presynapdc structures were not significandy altered.
3. The synaptic cleft was widened and contained debris that
appeared to be the terminals of the postsynaptic membrane.
In addition to the morphologic suggestion that a postsynaptic,
rather than presynaptic, abnormality was responsible for my-
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asthenia gravis, biochemical studies in the 1970s helped to localize and quantify the acetylcholine receptors. By studying the
mechanism of action of poisonous snake venom, Chang and Lee
found that alpha-bungarotoxin binds specifically and irreversibly to the acetylcholine receptor (3). This enabled the production of a labeled ligand for the acetylcholine receptor that bound
specifically and irreversibly, thereby allowing the identification
of acetylcholine receptors in normal and in myasthenic muscle.
Fambrough et al (4) documented that the acetylcholine receptors
in the postsynapdc membrane of myasthenic muscles were reduced to 10% to 30% of normal.
As technology for electrophysiology improved, Albuquerque
et al (5) were able to apply acetylcholine directly on to the
postsynaptic membrane by using Nomarsky Opdcs, which documented that the decrease in sensitivity was consistent with the
decrease in the number of acetylcholine receptors.
Thus, while it was firmly established by the mid 1970s that
myasthenia gravis was a postsynaptic disease of acetylcholine
receptors, the cause of this dysfunction was still unknown.
Much of the evidence pointed toward myasthenia gravis being an
autoimmune disease. This was first suggested in the late 1950s
when an increased prevalence of other autoimmune diseases in
myasthenic patients was noted. More evidence resulted from the
development of another cholinergic ligand from poisonous
snake venom. Like the alpha-bungarotoxin, alpha cobra toxin is
also a very specific ligand that binds to acetylcholine receptors.
However, because it is a reversible binding it was possible to attach alpha cobra toxin to a column and to purify acetylcholine
receptors. Since acetylcholine receptors are found in high concentrations in the organs of the electric ray and the electric eel,
it was therefore possible to use these electric organ tissues to
purify large amounts of acetylcholine receptors.
Patrick and Lindstrom (6), who conducted these experiments,
decided it would be interesting to study the acetylcholine receptor using a very specific antibody. Therefore, they attempted to
immunize rabbits to the acetylcholine receptor, but the rabbits
died consistently. From consultations with a neurologist, they
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found that myasthenia gravis was the cause of the weakness and
death ofthese rabbits. Thus, experimental autoimmune myasthenia gravis was discovered. Investigators found that in its
chronic phase experimental autoimmune myasthenia gravis is
morphologically, biochemically, and electrophysiologically
identical to the human form of the disease. The only difference
was in the acute phase of the experimental disease in which a
cellular infiltration of the end plate occurred. To our knowledge,
this does not occur in human myasthenia gravis.
Following these experiments, it was thought that myasthenia
gravis also might have an antibody to the acetylcholine receptor.
A variety of techniques were used to detect and quantify the antibodies that bind to the acetylcholine receptor in the serum of padents with myasthenia gravis. By using specific ligands, it was
possible to localize these antibodies to the end plate.
Finally, it became possible to transfer myasthenia gravis from
man to mouse by using purified antibodies and injecting them
chronically into mice. This experiment suggested that myasthenia gravis could be caused by a circuladng agent. Indeed,
about 15% of infants of myasthenic mothers are clinically weak
at birth or immediately following birth. These infants have transient neonatal myasthenia gravis which clears within three to six
weeks and is due to a circulating antibody.
With the discovery of antibodies against the acetylcholine receptor, it was believed that myasthenia gravis could be understood quite easily. It was inidally thought that these antibodies
would go into the neuromuscular junction, block the action of
acetylcholine, and produce a neuromuscular blockade. However, several factors suggested that the answer was not that simple. First, there is a poor correlation between the state of the
clinical disease and the titer of acetylcholine receptor antibodies
in the serum of these patients. Second, if serum andbodies from
a myasthenic padent are applied to a neuromuscular preparation
in vitro, no blockade is produced. Investigators thus presumed
that the antibody was involved in a more complicated process. It
was later documented that the andbodies that bound to the
acetylcholine receptor in the postsynaptic membrane acdvated
the lydc phase series of complement so that there was complement-mediated lysis of the postsynapdc membrane with actual
destrucdon of the tips of the membrane containing the acetylcholine receptors. A second group of experiments measuring the
turnover of acetylcholine receptors in muscle culture found that
acetylcholine receptor antibodies accelerated the degradation of
these receptors to a level two to four times as fast as expected
with normal serum. Therefore, at least two mechanisms were
known to produce the loss of acetylcholine receptors in the
postsynaptic membrane: the complement-mediated lysis, and
the receptor modulation by the antibody.
The uldmate acdon of the acetylcholine receptor andbodies is
sdll not understood. The presence of the antibody is not sufficient to explain or produce the disease. Patients who are in remission from the disease may have a very significant titer of the
antibody and yet have no myasthenia gravis. One possible
explanation is that acetylcholine receptors differ between one
patient and another, and that difference is what mediates the variation in disease.
There are several binding characterisdcs of acetylcholine receptors. These receptors can be blocking or nonblocking, ie.
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some will block the binding of alpha-bungarotoxin and some
will not. There are also two types of acetylcholine receptors: 1)
those which are found in normal innervated muscles, limited to
the neuromuscular junction; and 2) those which occur after denervation and spread across the muscle membrane. Studies have
found that myasthenic patients have antibodies with several different binding characterisdcs.
The acetylcholine receptor consists of an alpha subunit that
contains the acetylcholine binding site. Two of these alpha subunits, as well as three other subunits (beta, gamma, and delta),
are within the acetylcholine receptor. These receptor subunits
can be purified and used to produce the experimental autoimmune myasthenia gravis. The alpha subunit is the most effective
subunit in producing weakness in animals; however, the native
receptor is always more effective in producing the disease than
any of the subunits. Within a particular myasthenic patient,
most of the antibodies are directed toward an epitope referred to
as the main immunogenic region which resides on the alpha subunit. While some antibodies are directed toward the other subunits, they do not appear to be important in determining the
severity of the disease. Severity of disease is determined by
something other than the type or titer of andbody that is found
within a myasthenic patient.
Transient neonatal myasthenia gravis can help to explain the
significance of the different types of antibodies. While transient
weakness occurs in about 15% of infants of myasthenic mothers,
about 60% of these infants have antibodies to the acetylcholine
receptor Neither the degree to which the mother is weak nor the
level of her antibody titer determines whether or not transient
weakness occurs. One of our cases involved a mother who had a
significant titer of acetylcholine receptor antibodies but was in
total clinical remission and off all medication during the last half
of her pregnancy. Her infant, who had a slighdy lower dter of
antibody, was significantly weak and required treatment. Later,
as the acetylcholine receptor was metabolized, the infant improved. This case suggests that the same antibody can have different effects on different individuals. Even though the mother
was in remission, some of her antibodies circulated to the fetus,
producing weakness in the infant after birth. Thus, idendcal
antibodies can cause significant differences in the severity of
weakness in two individuals. The biologically acdve antibody
was present in the mother yet did not produce weakness. Therefore, host factors may be important in determining the clinical
state in myasthenic patients. Some ofthese host factors may be a
difference in the biochemistry of the motor end plate, ie, infants
have different types of motor end plates than adults. Other possibilides include either the hormonal background in which the
antibodies are acdng or other blocking factors. Studies have
shown that a significant percentage of myasthenic patients have
and-idiotypic antibodies circuladng against the acetylcholine
receptor andbody, and possibly these and-idiotypic antibodies
mediate a much more benign form of the disease in some
patients with myasthenia gravis.

Incidence
In their 1971 study of over 1,200 patients with myasthenia
gravis, Osserman and Genkins (7) observed that the distribudon
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of the incidence of myasthenia gravis is essendally a bimodal
curve, with a peak incidence among young women and a second
peak occurring among the elderly. In the latter group the sex distribution is essentially equal, although the incidence among elderly men tends to be somewhat higher We have also noted the
same bimodal curve, although in our series the age distribudon
increased by ten years, which may reflect that many of our patients began treatment at Henry Ford Hospital in the middle
rather than in earlier stages of the disease. We also observed that
myasthenia gravis affects two women per one man.

Symptomatology
One of the hallmarks of this disease, compared to other neuromuscular diseases, is that ocular muscles are characteristically involved. Alternating ptosis between the right and
the left eye is almost pathognomonic of myasthenia gravis.
Bulbar musculature is also affected. Symptoms may include
hoarseness, difficulty with chewing, swallowing, and holding
up the head, and respiratory crisis. Because patients are at high
risk for respiratory failure, being aware of the patient's respiratory status is the key to management of this disease. At one dme
myasthenia gravis had a mortality rate of 20% to 30%, mostly
due to respiratory failure and concurrent infection. A large
number of patients may have generalized skeletal muscle weakness as well, and this may occur at the onset or later on in the
course of the disease.

Classification
Myasthenia gravis has been classified in several different
ways. Osserman and Genkins" (7) classification of the disease is
commonly used. For adults, group 1 includes patients who have
weakness localized to the eye muscles, such as ptosis and diplopia. This group represents approximately 20% of all patients
with myasthenia gravis. If the disease has not progressed beyond
involvement ofthe eye muscles within two years after onset, it is
unlikely that the disease will progress further. Studies have
shown that ofthe more than 90% of patients presenting with
ocular findings, those who will progress to generalized myasthenia will do so by the end of two years. Group 2 includes
patients with generalized myasthenia; mild 2A and 2B represent
moderate severity with more bulbar symptoms. Group 3 includes those patients with a rapidly progressive course, usually
resulting in respiratory failure within the first six months to one
year after onset of the disease. Many of these padents have a
thymoma. Group 4 represents a late progressive form of myasthenia gravis in which the severity of symptoms gradually increases over a period of years. Typically, the greatest degree of
severity occurs within the first three years after onset.
A different type of classification, suggested recently by
Compston et al (8), is based on the genetics and immunology of
myasthenia gravis. Approximately 10% to 15% of myasthenic
patients have a tumor of the thymus. In group 1 of this classification, no sex prevalence, HLA predominance, or characteristic
HLA typing is seen. Groups 2 and 3 include patients without a
thymoma. These patients appear to have a genetic predisposidon toward acquiring myasthenia gravis. Those with onset before age 40 are predominately females. Patients in this age group
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have a 10% incidence of associated autoimmune diseases and
share certain HLA antigens. Those with onset after age 40 are
predominately males. The HLA types noted in this group are
different from those seen in the younger age group, and these
patients have a greater incidence of other associated autoimmune disea.ses.
In Osserman and Genkins' study (7), the more common associated autoimmune diseases included thyroid dysfunction (10%
to 15%), diabetes mellitus (6%), and rheumatoid arthritis (3%).
A smaller number of patients developed polymyosids, systemic
lupus, vitiligo, pernicious anemia, and sarcoidosis. A variety of
other autoimmune endocrine disorders have also been associated with myasthenia gravis.

Diagnosis
Myasthenia gravis is diagnosed in several steps. While associated autoimmune diseases should be considered in the initial
workup, the medical history and physical examination is the first
and most important step in diagnosing the disease. The second
step involves repetitive nerve stimulation or single fiber electromyogram (EMG) tests to document the neuromuscular
blockade. Repetitive stimulation, or the Jolly test, is carried out
by stimulating the nerve at 3 cycles/sec and recording the resultant compound action potential from muscle. Myasthenia gravis
would be diagnosed by seeing the typical decremental response.
Single fiber EMG is a more sophisticated means of determining
neuromuscular blockade and transmission failure. With proper
testing of appropriate muscles, results should be positive in
about 95% of patients with myasthenia gravis.
The anti-acetylcholine receptor antibody, the key figure in the
autoimmune aspect of this disorder, is present in about 90% of
patients with generalized myasthenia gravis and in about 50% of
patients with the disease limited to the eye muscles. Antistriated
muscle antibodies, discovered in the early 1960s, were the first
clue to the autoimmunity in myasthenia gravis. These antibodies
will stain muscle striations, such as the A band, the I band, and
the Z band. Interestingly, while these andbodies are present in
30% of patients with myasthenia gravis, they apparently do not
participate in the pathogenesis of the disease. Of patients with
myasthenia gravis who have a thymoma, 95% will also have the
antistriated muscle andbodies, although only 50% of patients
with antistriated muscle antibodies will have a thymoma. Thus,
the presence of antistriated muscle antibodies is a good marker
for the possible presence of a thymoma. For this reason, chest
x-ray and chest computed tomography are routine tests in the
evaluation of the patient with myasthenia gravis. While 10%
to 15% of patients will have a frank thymoma, another 70% of
patients will have an enlargement of the thymus, or thymic
hyperplasia.
Other diagnostic tests for myasthenia gravis include tests for
collagen vascular disease, thyroid function tests, and the tensilon test. The tensilon test involves injecdon of a short-acting
anticholinesterase which will improve neuromuscular transmission for about three to five minutes and thus aid in the diagnosis
of myasthenia gravis. Although the older literature reports that
the tensilon test is the key to diagnosing myasthenia gravis, this
test presents two problems: I) a large number of padents will
have a false-positive tensilon test because of the severe cho-
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linergic side effects of this drug, and 2) tensilon can cause respiratory failure in patients with compromised respiratory function. This can be a serious problem since some patients with
compromised respiratory function may escape detection at the
inidal examination.

Henry Ford Hospital Experience
Approximately 147 patients with myasthenia gravis were seen
at Henry Ford Hospital between 1983 and 1987, although that
number has risen to over 180 patients to date. This total represents perhaps 20% of all myasthenic patients in Michigan.
Clinic visits range between between 450 and 500 per year, which
indicates that many padents with this disease need to be seen
frequently. Whereas probably 50% of the padents are seen only
once or twice a year because they are in stable condition, the
others must be seen once a month or more often. We have approximately 25 hospital admissions per year, which includes
one or two patients with a respiratory crisis necessitating a prolonged hospital stay.
Of the 147 patients seen between 1983 and 1987, 44 padents
received thymectomies. A similar number were demonstrated to
have associated autoimmune diseases. Thyroid disease was
more prevalent in our group than in Osserman and Genkins'
group, which is likely not a significant difference. Other frequendy seen associated diseases included diabetes mellitus and
vidligo. A few padents had pernicious anemia, rheumatoid arthritis, and sarcoidosis. One patient had immune thrombocytopenic purpura, one had scleroderma, and one had
polymyositis.

Treatment
Several forms of treatment are used for myasthenia gravis.
The andcholinesterases, a purely symptomadc form of treatment, essentially augment the signal from nerve to muscle, stopping the breakdown of acetylcholine. Pyridosdgmine bromide
is the most commonly used anticholinesterase.
Thymectomy is another form of treatment. Abnormality of
the thymus was one of the early clues to the autoimmunity of
myasthenia gravis, and removal or irradiation of the thymus was
shown to ameliorate the course of the disease. Thus, thymectomy is recommended for virtually all patients with severe or
moderate myasthenia gravis. A recent study reported that thymectomy in patients without a thymoma increased the remission
rate after several years to between 30% and 50% (9).
Corticosteroids have an unusual affect on myasthenic padents. When corticosteroids are given in high doses from the
onset, within three days to two weeks about 30% to 50% of patients get weaker and 10% of these patients may develop respiratory crisis. However, most of these patients will improve after
three to six weeks of corticosteroid therapy, and as many as 50%
will go into remission. Unfortunately, corticosteroid therapy is
imperfect. It is difficult to discondnue steroids in these padents
after time. They become steroid-dependent, which leads to further complications.
Other immunosuppressive agents, pardcularly azathioprine,
have been used to treat myasthenia gravis, but this has been
much more popular in Europe than in the United States. While
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30% to 50% of patients may go into remission with azathioprine, it may take up to one year for maximum effect to occur
and patients can become dependent on the drug. Studies have
shown that discontinuation of azathioprine will often result in a
recurrence of the disease within six months.
We follow the principle that patients with ocular or very mild
myasthenia gravis may be treated symptomadcally, but an aggressive approach to the immune cause ofthe disease is important for patients with more severe myasthenia gravis. As mentioned previously, the key to management of myasthenia gravis
is being aware of whether or not these patients have any respiratory compromise. Respiratory compromise may not be obvious
when examining skeletal muscle involvement since respiratory
muscles can be involved out of proportion to any other skeletal
muscle involvement. However, one waming signal is when patients develop other bulbar symptoms such as difficulty with
chewing or swallowing.
For padents with mild myasthenia gravis, treatment includes
anticholinesterase therapy; thymectomy is also recommended
only for those with generalized myasthenia gravis. Patients with
the disease limited to the ocular muscles can be treated with andcholinesterases followed by small doses of steroids.
For those with moderate myasthenia gravis, thymectomy is
recommended, preferably early on in the course of the disease.
Andcholinesterase medications can be used as an adjunct, and
steroids can be used if these padents are functionally unable to
carry out their normal daily activities.
For padents with severe myasthenia gravis, the key is being
aware of their respiratory compromise and protecting them
against respiratory failure. These patients should be monitored
in the intensive care unit. Respiratory parameters should be
measured frequently in other patients who may be developing
respiratory insufficiency. Plasmapheresis may produce improvement in patients with severe myasthenia gravis; however,
improvement may not occur for seven days to two weeks because the neuromuscular blockade stems from a decreased
number of acetylcholine receptors and the end plate must be allowed to heal. Steroids, usually begun ih high doses, might also
be helpful for patients with severe myasthenia gravis. Anticholinesterase may not be u.seful for patients in respiratory crisis
since it may cause excessive bronchial secretions and make
treatment more difficult for these intubated padents. Thymectomy is not recommended until after these padents are in stable
condition. Azathioprine may also be considered as treatment for
the long term.
Why do some patients who have had stable myasthenia gravis
for a long period of time suddenly deteriorate? We have developed five categories to classify these types of patients. The first
category includes patients who simply have a worsening of their
myasthenia gravis. The second group includes patients who
have therapeutic complications. For example, patients with excess cholinergic effects from the andcholinesterases develop a
cholinergic blockade, which is manifested by other side effects
such as an excess in salivation and sweating, tearing, diarrhea,
and abdominal cramps. Also, patients may have a steroid myopathy or steroid-induced hypokalemia that produces excessive
weakness. The third group includes patients who become worse
because of changes in related diseases. Forexample, patients
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who develop thyroid dysfunction, such as hyperthyroidism or
hypothyroidism, may have a worsening of myasthenia gravis.
The fourth group includes patients who become worse becau.se
of unrelated diseases. Any other intercurrent infecdon, pardcularly upper respiratory infections or pneumonia or even dental
abscesses, can lead to respiratory crisis. In fact, any unrelated
disease, such as cancer or stroke, can cause myasthenia gravis to
worsen. The fifth group includes patients who become worse
because of side effects of medication. While aminoglycoside antibiotics, which are neuromuscular blockers, do not present
problems to the nonmyasthenic patient who has ten dmes more
acetylcholine receptors than are needed, for the myasthenic padent who has only 10% to 20% of the normal number of acetylcholine receptors, a blockade of 30% or 40% of those receptors
may produce a significant effect. Other medications that can
produce weakness in myasthenic padents include beta blockers
and membrane stabilizers.
Potential new treatments for myasthenia gravis include
cyclosporine, specific plasmapheresis, and specific immunotherapy. Cyclosporine has been tried, but its effects are not
sufficient to use as the sole agent for treatment of myasthenia
gravis. A clinical trial will be undertaken in the near future to
investigate the use of cyclosporine as a replacement for steroids.
Plasmapheresis with specific filters may also be used in the future. In this procedure, the acetylcholine receptors are bound to
the filters so that only the antibodies against the acetylcholine
receptors will be removed, which obviates the need for plasma
replacement. Specific immunotherapy to induce competing
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andbodies or and-idiotypic antibodies has also been suggested.
Immunizadon of animals with denatured acetylcholine receptors has already been shown to ameliorate the course of experimental autoimmune myasthenia gravis.
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